$3.98 +0.10 (2.58%) Sunesis Pharmaceuticals Inc - NASDAQ

Dec. 7, 2016 | 03:59 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 3.98
Trade Time: Dec 07 03:59 PM Eastern Daylight Time
Change: +0.10 (2.58%)
Prev Close: 3.88
Open: 3.88
Bid: 3.97
Ask: 4.00
  1. No results found.
  1. Sunesis Announces Pricing Of $25 Million Offering Of Securities

    TalkMarkets | Oct. 19, 2016 | 15:23PM EST
  2. Morning Call For October 19, 2016

    TalkMarkets | Oct. 19, 2016 | 08:03AM EST
  3. Roundys Among Largest Insiders' Buys of the Week

    GuruFocus | Dec. 31, 2015 | 12:35PM EST
  4. Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe

    Benzinga | Dec. 8, 2015 | 07:02AM EST
  5. Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:41AM EST
  6. Sunesis Pharma Reports Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at CFS

    Benzinga | Nov. 4, 2015 | 18:02PM EST
  7. Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End

    Benzinga | Oct. 7, 2015 | 15:05PM EST
  8. Biotech Stocks Falling Broadly, Here's Why And How Much

    Benzinga | Jul. 26, 2015 | 20:57PM EST
  9. Worst Performing Industries For July 24, 2015

    Benzinga | Jul. 24, 2015 | 10:30AM EST
  10. Sunesis Pharma Offers New Data from VALOR Trial for Vosaroxin in Oilder Patients with Acute Myeloid Leukemia

    Benzinga | Jun. 12, 2015 | 06:01AM EST
  11. Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

    Benzinga | May. 21, 2015 | 07:13AM EST
  12. BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will Be Breakeven By 2017'

    Benzinga | Jan. 5, 2015 | 19:19PM EST
  13. Sunesis Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS at ASH Annual Meeting

    Benzinga | Dec. 8, 2014 | 13:32PM EST
  14. Morning Market Losers

    Benzinga | Dec. 8, 2014 | 09:53AM EST
  15. UPDATE: Sunesis Reports Schedule C Had Most Favorably Safety/Efficacy Balance

    Benzinga | Nov. 24, 2014 | 07:24AM EST
Trading Center